Effect of anti-HPV16 E6-ribozyme on cell proliferation and invasiveness of cervical carcinoma cell line CaSKi

Abstract

Abstract: Objective To investigate the effects of anti-HPV16-ribozyme on the cell proliferation and invasiveness of cultured cervical cancer cell line CaSKi. Methods CaSKi cells were transfected with anti-HPV16 E6-ribozyme and empty eukaryotic expression plasmids via lipofectin and designated as CaSKi-R and CaSKi-P cells respectively. The growth rate, cell colony-forming ability on soft agar, invasiveness and tumorigenicity of CaSKi-R, CaSKi-P, and CaSKi cells were studied using corresponding methods. The expressions of cox-2 and vascular endothelial growth factor (VEGF) mRNA of the 3 cell strains were determined with one-step reverse transcriptional PCR (RT-PCR), and immunocytochemistry was employed for detecting the expressions of COX-2 and VEGF antigens. Results No distinct differences in the growth rate, colony-forming ability on soft agar, cell invasiveness and tumorigenicity were observed between CaSKi and CaSKi-P cells, whereas by comparison, CaSKi-R cells exhibited decreased growth rate, colony-forming ability, the cell invasiveness and tumorgenicity, with also lowered expression levels of cox-2 and VEGF mRNA as shown by RT-PCR analysis. Expressions of COX-2 and VEGF antigens were detected in all the 3 cell strains immunocytochemically, but compared with CaSKi and CaSKi-P cells, the antigen expressions in CaSKi-R cells were significantly weaker. Conclusion Anti-HPV16 E6-ribozyme may partially inhibit the prolifera- tion and reduce the invasiveness of CaSKi cells possibly through decreasing cox-2 and VEGF expressions, which are the important agents for tumor invasion.

CLC Number:

R737.33

LIU Ke¹, WANG Li-li², SUN Fang¹, ZHENG Yan-fang³, ZHANG Ji-ren³. Effect of anti-HPV16 E6-ribozyme on cell proliferation and invasiveness of cervical carcinoma cell line CaSKi[J]. Journal of Southern Medical University, 2004, 24(12): 1367-1372.

References

[1] Alani RM, Munger K. Human papillomavirus and associated malignancies[J]. J Clin Oncol, 1998, 16(1): 330-7.
[2] 郑燕芳,张积仁,屈良鹄,等.两种抗HPV核酶的设计、表达与活性鉴定[J].中华实验与临床病毒学杂志,1999,13(2):238,242.Zheng YF, Zhang JR, Qu LH, et al. The design, expression and activity evaluation of two kinds ofanti-HPV ribozyme [J]. Chin J Exp Clin Virol, 13(2): 238,242.
[3] 郑燕芳,饶智国,张积仁.特异性核酶对宫颈癌细胞系Caski增殖与凋亡的影响[J].第一军医大学学报,2002,22(6):496-502.Zheng YF, Rao ZG, Zhang JR. Effects of anti-HPV16 E6-ribozymeon the proliferation and apoptosis of human cervical cancer cell line Caski [J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao,2002, 22(6): 496-502.
[4] Albini A, Iwamoto Y, Kleinman HK, et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells [J]. Cancer Res,1987, 47(12): 3239-45.
[5] Chen Z, Kamath P, Zhang S, et al. Effects on tumor cells of ribozymes that cleave the RNA transcripts of human papillomavius type 18[J].Cancer Gene Therapy, 1996, 3(1): 18-23.
[6] Zheng YF,Zhang JR,Qu LH,et al. Effectiveness ofa ribozyme for cleavage of an RNA transcript from human papillomavirus type 16[J]. Int J Modern Cancer Ther, 1998, 1(1): 134-8.
[7] 郑燕芳,饶智国,张积仁.抗HPV16E6核酶对宫颈癌细胞恶性表型的影响[J].中国肿瘤生物治疗杂志,2002,9(3):183-5.Zheng YF, Rao ZG, Zhang JR. The effect of anti-HPV16 E6- ribozyme on malignant phenotypes of cervical carcinoma cell line[J]. Chin J Cancer Biother, 2002, 9(3): 183-5.
[8] Tokumo K, Kodama J, Seki N, et al. Different angiogenic pathways in human cervical cancers [J]. Gynecol Oncol, 1998,68(1): 38-44.
[9] Santin AD, Hermonat PL, Ravaggi A, et al. Secretion of vascular endothelial growth factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix [J]. Obstet Gynecol, 1999, 94(1):78-82.
[10] Ueda M, Terai Y, Yamashita Y, et al. Correlation between vascular endothelial growth factor-C expression and invasion phenotype in cervical carcinomas[J]. Int J Cancer, 2002, 98(3): 335-43.
[11] Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2[J]. Cell, 1995, 83(3): 493-501.
[12] Jaime LM, Kathleen ML, Mane TK, et al. Antiangiogentic and antitumor of cyclooxygenas-2 inhhibitors [J]. Cancer Res, 2000, 60:1306-11.
[13] 饶智国,张积仁,郑燕芳,等.抗HPV16E6核酶对宫颈癌Caski细胞化疗的影响[J].第一军医大学学报,2002,22(4):316-9Rao ZG, Zhang JR, Zheng YF, et al. Effect of anti-HPV16 E6-ribozyme on the sensitivity of cervical carcinoma cell line to chemotherapy[J]. J First Mil Med Univ/Di Yi Jun Yi Da Xue Xue Bao, 2002, 22(4): 316-9.

[1]	. [J]. Journal of Southern Medical University, 2006, 26(12): 1772-1773.
[2]	ZHANG Yu1, ZHANG Yi1, LIN Qiu-hua2 1Department of Obstetrics and Gynecology, Xiangya Hospital, 2Department of Obstetrics and Gynecology, Second Xiangya Hospital, Central South University, Changsha 410078, China. Progesterone-modulated proteins in human endometrial cancer cell line Ishikawa [J]. Journal of Southern Medical University, 2006, 26(08): 1110-1113.
[3]	LU Jin-li1, YANG Fang2 Department of Radiotherapy, First Hospital1, Western District Library2, Xi’an Jiaotong University, Xi’ an 710061, China. Clinical pharmacokinetic study of cisplatin in enhancing cervical cancer radiosensitivity [J]. Journal of Southern Medical University, 2006, 26(08): 1170-1172.
[4]	. [J]. Journal of Southern Medical University, 2006, 26(08): 1248-1249.
[5]	GUO Sui-qun1, XING Fu-qi1, PANG Zhan-jun1, FANG Wei-yi2, LIU Guo-bing1 1Department of Gynaecology and Obstetrics, Nanfang Hospital, 2Institute of Cancer Research, Southern Medical University, Guangzhou 510515, China. Preliminary study of gene expression profiling in human type I and II endometrial carcinoma [J]. Journal of Southern Medical University, 2006, 26(06): 734-737.
[6]	WANG Ying, LI Xu, CHEN Wei Medical Laboratory Center, First Hospital of Xi’an Jiaotong University, Xi’an 710061, China. Expression, structure prediction and functional analysis of murine single-chain fragment vari- able antibody against human cervical cancer [J]. Journal of Southern Medical University, 2006, 26(01): 16-21.
[7]	LIU Guo-bing, LIU Xin, PANG Zhan-jun, XING Fu-qi. Significance of pelvic lymph node human papillomavirus DNA detection in cervical cancer [J]. Journal of Southern Medical University, 2005, 25(10): 1236-1239.
[8]	LIU Xin, LIU Guo-bing, PANG Zhan-jun, XING Fu-qi. Sequence polymorphism of human papillomavirus type 16 E7 in cervical cancer [J]. Journal of Southern Medical University, 2005, 25(10): 1272-1275.
[9]	LANG Yan¹, XIONG Yong-yan¹, CHEN Hui-zhen². Association between expression of survivin and high-risk human papillomavirus infection in cervical cancer and precancerous tissues [J]. Journal of Southern Medical University, 2005, 25(10): 1276-1279.
[10]	ZHAO En-feng¹, BAO Lei², LI Chao, SONG Lei³, LI Ya-li¹. Changes in epidemiology and clinical characteristics of cervical cancer over the past 50 years [J]. Journal of Southern Medical University, 2005, 25(06): 605-609.
[11]	ZHENG Xiao-kang¹, CHEN Long-hua¹, LI Jian². Radiotherapeutic effect and prognosis of bulky exophytic cervical cancer [J]. Journal of Southern Medical University, 2005, 25(03): 332-334,338.
[12]	ZHOU Jin¹, CHEN Shi-ling¹, XING Fu-qi¹, PANG Zhan-jun¹, LI Bing², ZHOU Wen-qu², FU Xin², DING Yan-qing³. Association of the novel hydatidiform mole-related gene F10 with the invasiveness of trophoblastic tumor [J]. Journal of Southern Medical University, 2005, 25(02): 171-173.
[13]	. Diagnostic analysis of two sister pairs with endometrial cancer [J]. Journal of Southern Medical University, 2005, 25(02): 239-240.
[14]	ZHOU Rui-li, LIU Guo-bing. Age and prognosis: analysis of their association in 93 cases of cervical cancer [J]. Journal of Southern Medical University, 2004, 24(09): 1066-1067.
[15]	ZHANG Guang-liang¹, LIU Guo-bing¹, HUANG Qi-li², XING Fu-qi¹. Comparative study of the impacts of laparoscopic and open laparotomic surgeries on oxidative stress in patients with uterine myomas [J]. Journal of Southern Medical University, 2004, 24(08): 907-909.